Investigational Drug Information for HMPL-523
✉ Email this page to a colleague
What is the development status for investigational drug HMPL-523?
HMPL-523 is an investigational drug.
There have been 12 clinical trials for HMPL-523.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2021.
The most common disease conditions in clinical trials are Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, and Neoplasms. The leading clinical trial sponsors are Hutchison Medipharma Limited, Hutchmed, and Iqvia Pty Ltd.
Summary for HMPL-523
| US Patents | 0 |
| International Patents | 38 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-10-01) |
| Vendors | 19 |
Recent Clinical Trials for HMPL-523
| Title | Sponsor | Phase |
|---|---|---|
| Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects | Hutchmed | Phase 1 |
| HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study | Hutchmed | Phase 1 |
| HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Hutchison Medipharma Limited | Phase 2/Phase 3 |
Clinical Trial Summary for HMPL-523
Top disease conditions for HMPL-523
Top clinical trial sponsors for HMPL-523
US Patents for HMPL-523
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for HMPL-523
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| HMPL-523 | Australia | AU2012266941 | 2031-06-08 | ⤷ Sign Up |
| HMPL-523 | Brazil | BR112013031405 | 2031-06-08 | ⤷ Sign Up |
| HMPL-523 | Canada | CA2836227 | 2031-06-08 | ⤷ Sign Up |
| HMPL-523 | Chile | CL2013003512 | 2031-06-08 | ⤷ Sign Up |
| HMPL-523 | China | CN103596952 | 2031-06-08 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
